Loading...
Market
Main competitor for Ascendis Pharma in hypoparathyroidism treatment by end of 2024?
2
Resolution / Starting Odds
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
Industry reports and market analysis from sources like MarketWatch or Statista
Story
FDA Approves Ascendis Pharma's YORVIPATH, Stock Surges 11.8% Premarket
Aug 12, 2024, 11:53 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults. This approval marks a significant milestone as it fills the gap left by Takeda's withdrawal of its treatment for the same condition. The announcement has led to a notable increase in Ascendis Pharma's stock, which surged over 11.8% in premarket trading. Hypoparathyroidism is a rare hormone disorder, and YORVIPATH® will now be the only approved treatment available in the U.S. for this condition.
View original story
Similar markets
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
No acquisition • 25%
FDA Approval • 25%
EMA Approval • 25%
Phase 4 Trial Initiation • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Eli Lilly • 25%
Sanofi • 25%
AstraZeneca • 25%
Other • 25%